A new study has revealed that a nasal spray formulation of ketamine demonstrates promise in the rapid treatment of symptoms of major depression and suicidal thoughts.
In this week’s round-up, we cover the latest industry news from depression and Parkinson’s disease. Find out more about our selection of the highlights this week.
A recent study has reported that long-term consumption of caffeine has negative effects for Alzheimer’s disease, potentially worsening the neuropsychiatric symptoms in those affected by the disorder.
Antidepressants are an effective treatment route for depression, novel study claims.
Researchers from Queensland University of Technology have identified a drug that could reverse the damaging effects of heavy alcohol consumption on neurogenesis.
Balovaptan, a molecule being developed by Roche for autism spectrum disorder, has been given FDA approval in order to accelerate its development.
This case report from Neurodegenerative Disease Management examines the suicide of a patient with early-onset Alzheimer’s disease in the context of planned versus impulsive acts in cognitive disorders.
In this research article from Personalized Medicine, explore how disorders such as depression and schizophrenia have been linked to specific neurotransmitter receptor variations.
In these interviews, we speak to four early career researchers whose respective research findings were highlighted by the Society as ones to watch in the coming years.
In this research article from Journal of Comparative Effectiveness Research, learn how differing drug treatments influence the quality of life of schizophrenia patients.